Constance Okeke, MD
Ophthalmology · Norfolk, VANPI 1851328132
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.0%), consulting fees and grants — rather than concentrated in one kind of arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 20.9%. 2025 is the largest year on record at $235,633, 2.8 times the $84,429 reported in 2019. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 692 payments — averaging $1156.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$167K
- AbbVie$133K
- Alcon$92K
- Sight Sciences, Inc.$87K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$83K
- Aerie Pharmaceuticals, Inc.$79K
- plus $159K from 35 others
Across 26 payments — averaging $2690.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$37K
- Glaukos Corporation$17K
- Bausch Health US, LLC$10K
- Sight Sciences, Inc.$3K
- Bausch & Lomb Americas Inc.$3K
What the payments were for
- Consulting fees$292,80737%
- Speaking & faculty fees$360,15845%
- Grants$86,02411%
- Travel & lodging$46,0046%
- Food & beverage$15,1632%
- Education$1620%
- Gifts$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$225,459
- Rocklatan$143,635
- Rhopressa$136,859
- DURYSTA$96,932
- OMNI(R) SURGICAL SYSTEM (US)$86,500
- SIMBRINZA$31,992
- XEN GLAUCOMA TREATMENT SYSTEM$29,478
- SION SURGICAL INSTRUMENT$25,000
- Travoprost Intraocular Implant - iDose$21,738
- iStent inject Trabecular Micro-Bypass Stent System$21,000
- Kahook Dual Blade$18,245
- Ahmed Glaucoma Valve$18,245
- iDose$13,689
- Clearpath$12,995
- Streamline$12,995
- Via360$12,245
- Clareon$6,423
- Streamline Surgical System$5,250
- AcrySof$5,130
- ARGOS$4,560
How this compares
$800,380 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 145 | $84,057 |
| RestasisCyclosporine | 72 | $80,253 |
| RhopressaNetarsudil Mesylate | 163 | $79,087 |
| VyzultaLatanoprostene Bunod | 149 | $64,051 |
| LumiganBimatoprost | 113 | $53,164 |
| XiidraLifitegrast | 38 | $47,212 |
| MieboPerfluorohexyloctane/Pf | 54 | $41,130 |
| CombiganBrimonidine Tartrate/Timolol | 85 | $34,974 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 97 | $21,850 |
| Prednisolone Acetate | 351 | $21,223 |
| Methazolamide | 71 | $21,211 |
| Brimonidine Tartrate | 410 | $19,849 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 80 | $19,806 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 101 | $17,788 |
| Pilocarpine Hcl | 208 | $12,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $132,969 | $175,220290 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $78,792 | $163,144308 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $167,203 | $152,393241 claims |
| AlconSimbrinza | $91,834 | $19,80680 claims |
| Thea Pharma Inc.Iyuzeh | $935 | $12,08726 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $417 | $9,61411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Kapil KapoorNorfolk$64K
- Albert CheungNorfolk$23K
- Samantha DewundaraNorfolk$19K
- Arielle SpitzeNorfolk$10K
- Rohit AdyanthayaNorfolk$6K
- Ethnie JonesRichmond$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.